ABCs in Dermatology

Chronic spontaneous urticaria treatment now spans 3 systemic options after a major international guideline update.

Angelika Erwin, MD, PhD, joins the podcast to discuss diagnosing and managing EPP and XLP on ABCs in Dermatology.

Hosts discuss the latest data in psoriasis and the case for treating scalp, nail, and genital psoriasis as systemic-eligible disease.

New AD biologic data highlight early systemic treatment, durable itch control, and improved pediatric growth—shifting goals beyond skin clearance.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

Experts unpack biologics, molecular know-how, and patient trust—plus key previews for the upcoming AAD Annual Meeting.